Vaccine hesitancy in parents can lead to under-vaccination or the complete lack of vaccination in children and adolescents. This has been linked to outbreaks of vaccine-preventable diseases. Pediatric and school nurses are often the main source of information for parents …
Neuromyelitis optica spectrum disorder (NMOSD) is a relatively new term for a group of rare, demyelinating autoimmune diseases affecting the central nervous system (CNS), particularly the optic nerves and spinal cord. In the past, NMOSD was conflated with multiple sclerosis …
Anemia occurs frequently in patients with inflammatory bowel disease (IBD) and is one of the most commonly seen extraintestinal manifestations of disease with iron deficiency (ID) as the most common cause. Practice guidelines recommend screening all patients with IBD regularly …
In the treatment of Alzheimer’s disease (AD), health care professionals are in dire need of clinical confidence in the evidence-based potential of novel disease-modifying therapeutic options. Several promising classes of emerging agents such as amyloid-targeting humanized monoclonal antibodies (mAbs), incretin-based …
Dementia is most commonly caused by Alzheimer’s disease (AD), a multifactorial progression of neurodegeneration in which the accumulation of amyloid-beta and tau proteins in the brain and chronic and dysregulated inflammatory processes lead to significant cognitive impairment. Though novel diagnostic …
Interleukin (IL)-23 has been identified as a main driver of inflammation in the pathology of inflammatory bowel disease (IBD). While all agents in this anti-IL-23 class neutralize IL-23 by binding of the Fab fragment, differences in Fc fragment may be …
Up to 80% of patients with Crohn’s disease (CD) report some degree of bowel urgency, a symptom that not only significantly adds to their overall emotional and social burden but can be an indicator of uncontrolled bowel inflammation. Unfortunately, bowel …
Cytokines, such as interleukin (IL)-23, are key drivers of intestinal inflammation in patients with inflammatory bowel disease. While all IL-23–targeted agents neutralize IL-23, differences in antibody structure can improve the ability of these agents to capture this inflammatory cytokine from …
Cytokines, such as interleukin (IL)-23, are key drivers of intestinal inflammation in patients with inflammatory bowel disease. While all IL-23–targeted agents neutralize IL-23, differences in antibody structure can improve the ability of these agents to capture this inflammatory cytokine from …